TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

BACKGROUND. When carcinoid syndrome (CS) diarrhea (CSD) is inadequately controlled with long‐acting somatostatin analogs (SSAs), clinical practice guidelines recommend addition of the tryptophan hydroxylase inhibitor telotristat ethyl (TE). In a 12‐week multinational, randomized controlled trial, TE...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Strosberg, Jonathan, Joish, Vijay N., Giacalone, Susan, Perez‐Olle, Raul, Fish‐Steagall, Ann, Kapoor, Kanika, Dharba, Sam, Lapuerta, Pablo, Benson, Al B.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853091/
https://ncbi.nlm.nih.gov/pubmed/31189618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0921
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados